Ovarian cancer is a rare but fatal gynecological malignancy and ranks 5th in cancer-related deaths in females. In over 70% of the cases identified, metastasis has already occurred before the initial diagnosis is made. Resistance (both intrinsic and acquired) further contributes to cancer-related deaths. Thus, early diagnosis, reliable models for assessing novel therapeutic modalities, and biomarker development for screening and to track therapeutic efficacy are critical clinical needs in ovarian cancer. 

The progress made in ovarian cancer research and treatments has been unprecedented, but there is still a need for standardized methods and tools. Creating a platform where investigators can share their experiences with various cell lines, in vitro and in vivo models will help in optimal planning and execution of the idea in the most effective manner. Streamlining a detailed protocol and sharing it with the scientific fraternity will enhance investigators' productivity and trouble-shooting capabilities at a global level. 

This special issue is being proposed with the vision to allow investigators across the world to share technical details on in vitro/in vivo model designs and novel treatment modalities to improve therapeutic outcomes in ovarian cancer, including but not limited to the following:

Isolation of primary cells from tumors derived from ovarian cancer patients

• Isolation of fibroblast/stromal cells from patient tumor
• Spheroids/organoids of tumors derived from patients and established cell lines
• Co-culture of tumor cells with macrophages, fibroblasts, and other stromal cells
• A mouse model for high-grade serous (HGS) ovarian cancers
• Proteomics/Mass-spectrometry
• Genomics/RNA-seq/sc-Seq/whole-genome mapping